Russia may have achieved a medical breakthrough with Enteromix, a personalized mRNA-based cancer vaccine that has shown 100% efficacy and safety in clinical trials. Built on technology similar to COVID-19 vaccines, it works by teaching the immune system to recognize and destroy cancer cells. The vaccine now awaits final approval from the Ministry of Health.
The Federal Medical and Biological Agency (FMBA) announced that Enteromix is ready for clinical use. Agency head Veronica Skvortsova confirmed that preclinical studies proved its safety and effectiveness, showing tumor shrinkage, slowed cancer growth, and safe repeated use.
Unlike standard cancer treatments such as chemotherapy or radiation, Enteromix has no serious side effects. Patients tolerated it well, offering a major advantage over traditional methods.
The vaccine is personalized, designed according to each patient’s RNA. The first version will target colorectal cancer, while other versions are in development for glioblastoma, a type of brain cancer, and certain melanomas, a form of skin cancer.
Trials began with 48 volunteers earlier this year. They were conducted by the National Medical Research Radiology Centre under the Ministry of Health, together with the Engelhardt Institute of Molecular Biology (EIMB) at the Russian Academy of Sciences.
The official announcement was made at the St. Petersburg International Economic Forum (SPIEF 2025) in June, where Russia highlighted its advances in medical science and biotechnology.
A report in MedPath noted that Enteromix uses four harmless viruses to attack tumors while boosting the immune system. Years of testing showed it can slow cancer growth and, in some cases, completely destroy it.
With trials successfully completed, the only step left is regulatory clearance. If approved, Enteromix will become the world’s first personalized mRNA cancer vaccine, potentially transforming cancer treatment worldwide.
